DNAtrix

Jan 13, 2020

DNAtrix Appoints Jeff Knapp as Chief Executive Officer and to Board of Directors

Nov 11, 2019

DNAtrix to Present Updated Results from the Phase 2 CAPTIVE / KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

Nov 13, 2018

DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer

Nov 07, 2018

Effectiveness of DNAtrix's DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer

May 08, 2018

Successful Delivery of DNAtrix's Oncolytic Virus DNX-2401 to Pediatric Brain Tumors

Apr 12, 2018

Effectiveness of DNAtrix Oncolytic Virus DNX-2440 Armed with OX40L to be Presented at the 2018 Annual Meeting of the American Association for Cancer Research

Dec 05, 2017

DNAtrix Announces First Pediatric Patient Treated with Oncolytic Virus DNX-2401

Nov 20, 2017

Mechanism of Action Studies for DNAtrix's Oncolytic Virus DNX-2401 Presented at the 2017 Society for Neuro-Oncology Annual Meeting

Jun 01, 2017

DNAtrix to Present Results of DNX-2401 for Recurrent Glioblastoma at ASCO 2017